Maggie Stanislawski
Concepts (508)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Microbiome | 10 | 2026 | 771 | 2.570 |
Why?
| | Microbiota | 9 | 2026 | 781 | 1.730 |
Why?
| | Body Mass Index | 11 | 2026 | 2438 | 1.620 |
Why?
| | Obesity | 12 | 2026 | 3082 | 1.580 |
Why?
| | Weight Loss | 3 | 2026 | 837 | 1.210 |
Why?
| | Overweight | 2 | 2026 | 609 | 0.770 |
Why?
| | Life Style | 1 | 2025 | 479 | 0.750 |
Why?
| | Percutaneous Coronary Intervention | 11 | 2020 | 543 | 0.720 |
Why?
| | United States Department of Veterans Affairs | 14 | 2020 | 768 | 0.700 |
Why?
| | Behavior Therapy | 2 | 2021 | 299 | 0.690 |
Why?
| | Fatty Liver | 2 | 2021 | 251 | 0.660 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2021 | 87 | 0.650 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2025 | 2584 | 0.650 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2023 | 365 | 0.580 |
Why?
| | Feces | 5 | 2025 | 513 | 0.560 |
Why?
| | Biostatistics | 1 | 2018 | 19 | 0.560 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2025 | 2147 | 0.550 |
Why?
| | Coronary Artery Disease | 6 | 2023 | 741 | 0.510 |
Why?
| | Pacemaker, Artificial | 4 | 2020 | 126 | 0.510 |
Why?
| | Weight Gain | 2 | 2018 | 559 | 0.500 |
Why?
| | Multifactorial Inheritance | 4 | 2025 | 203 | 0.500 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 208 | 0.480 |
Why?
| | Insulin Resistance | 3 | 2024 | 1241 | 0.480 |
Why?
| | Risk Factors | 18 | 2025 | 10792 | 0.460 |
Why?
| | Bacteria | 3 | 2020 | 889 | 0.460 |
Why?
| | Middle Aged | 34 | 2026 | 35928 | 0.450 |
Why?
| | Glucose Oxidase | 7 | 1994 | 25 | 0.440 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 266 | 0.440 |
Why?
| | Phylogeny | 2 | 2018 | 1019 | 0.440 |
Why?
| | Prosthesis-Related Infections | 4 | 2020 | 99 | 0.430 |
Why?
| | Female | 51 | 2026 | 78376 | 0.420 |
Why?
| | Pediatric Obesity | 2 | 2019 | 638 | 0.420 |
Why?
| | Male | 44 | 2026 | 72406 | 0.410 |
Why?
| | Asthma | 1 | 2025 | 1768 | 0.410 |
Why?
| | Antibiotic Prophylaxis | 3 | 2020 | 129 | 0.410 |
Why?
| | Humans | 64 | 2026 | 144957 | 0.400 |
Why?
| | Liver | 9 | 2020 | 1888 | 0.400 |
Why?
| | RNA, Ribosomal, 16S | 5 | 2018 | 559 | 0.400 |
Why?
| | Veterans Health | 4 | 2018 | 189 | 0.390 |
Why?
| | Phenotype | 6 | 2023 | 3164 | 0.380 |
Why?
| | Lactoperoxidase | 7 | 1994 | 7 | 0.370 |
Why?
| | Peroxidases | 5 | 1993 | 29 | 0.330 |
Why?
| | Coronary Artery Bypass | 4 | 2017 | 269 | 0.320 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2025 | 653 | 0.320 |
Why?
| | Aged | 27 | 2025 | 25947 | 0.320 |
Why?
| | Pregnancy | 7 | 2021 | 7191 | 0.310 |
Why?
| | Adult | 15 | 2026 | 40506 | 0.310 |
Why?
| | Immunotoxins | 4 | 1990 | 55 | 0.300 |
Why?
| | Dextrans | 5 | 1988 | 86 | 0.290 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2171 | 0.290 |
Why?
| | Veterans | 7 | 2018 | 1603 | 0.280 |
Why?
| | Immunoglobulin Idiotypes | 7 | 1988 | 28 | 0.270 |
Why?
| | Genetic Predisposition to Disease | 4 | 2025 | 2365 | 0.270 |
Why?
| | Bifidobacterium | 2 | 2017 | 21 | 0.270 |
Why?
| | Cohort Studies | 7 | 2025 | 5965 | 0.260 |
Why?
| | Myocardial Infarction | 6 | 2018 | 1209 | 0.260 |
Why?
| | United States | 21 | 2025 | 15988 | 0.250 |
Why?
| | Coronary Angiography | 7 | 2020 | 323 | 0.250 |
Why?
| | Genome-Wide Association Study | 5 | 2025 | 1407 | 0.240 |
Why?
| | Mississippi | 2 | 2025 | 29 | 0.230 |
Why?
| | Anti-Infective Agents | 2 | 2020 | 242 | 0.230 |
Why?
| | Radial Artery | 2 | 2017 | 70 | 0.220 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 550 | 0.210 |
Why?
| | Defibrillators, Implantable | 2 | 2020 | 382 | 0.210 |
Why?
| | Time Factors | 11 | 2021 | 7183 | 0.210 |
Why?
| | T-Lymphocytes | 8 | 1995 | 1982 | 0.210 |
Why?
| | Diet | 3 | 2023 | 1275 | 0.210 |
Why?
| | Longevity | 1 | 2025 | 173 | 0.200 |
Why?
| | HIV-1 | 3 | 1995 | 896 | 0.200 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5872 | 0.200 |
Why?
| | Metabolomics | 2 | 2026 | 727 | 0.200 |
Why?
| | Logistic Models | 3 | 2025 | 2119 | 0.200 |
Why?
| | Risk Assessment | 4 | 2021 | 3676 | 0.200 |
Why?
| | Child | 6 | 2021 | 22657 | 0.190 |
Why?
| | Plasmacytoma | 8 | 1989 | 19 | 0.190 |
Why?
| | Registries | 3 | 2019 | 2385 | 0.190 |
Why?
| | Age Factors | 2 | 2021 | 3335 | 0.180 |
Why?
| | Metagenomics | 1 | 2023 | 181 | 0.180 |
Why?
| | Machine Learning | 2 | 2026 | 587 | 0.180 |
Why?
| | Norway | 2 | 2018 | 45 | 0.180 |
Why?
| | Patient Identification Systems | 2 | 2019 | 16 | 0.180 |
Why?
| | Mothers | 2 | 2018 | 775 | 0.170 |
Why?
| | Electronic Health Records | 2 | 2020 | 1177 | 0.170 |
Why?
| | Acute Kidney Injury | 2 | 2020 | 866 | 0.170 |
Why?
| | Proton Therapy | 1 | 2021 | 15 | 0.170 |
Why?
| | Diet, Reducing | 1 | 2021 | 91 | 0.170 |
Why?
| | Waist Circumference | 1 | 2021 | 139 | 0.170 |
Why?
| | Incidence | 4 | 2021 | 2883 | 0.170 |
Why?
| | Computational Biology | 1 | 2026 | 681 | 0.160 |
Why?
| | Adiposity | 1 | 2025 | 543 | 0.160 |
Why?
| | Gardening | 1 | 2020 | 13 | 0.160 |
Why?
| | Software | 1 | 2026 | 692 | 0.160 |
Why?
| | Prospective Studies | 4 | 2025 | 7997 | 0.160 |
Why?
| | DNA, Bacterial | 2 | 2018 | 342 | 0.160 |
Why?
| | Caloric Restriction | 1 | 2021 | 127 | 0.160 |
Why?
| | Fasting | 1 | 2021 | 277 | 0.150 |
Why?
| | Mice, Inbred BALB C | 14 | 1989 | 1253 | 0.150 |
Why?
| | Western World | 1 | 2019 | 7 | 0.150 |
Why?
| | Atherosclerosis | 1 | 2023 | 409 | 0.150 |
Why?
| | Weight Reduction Programs | 1 | 2021 | 137 | 0.150 |
Why?
| | Precision Medicine | 1 | 2023 | 458 | 0.150 |
Why?
| | Cardiac Catheterization | 3 | 2018 | 560 | 0.150 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2019 | 19 | 0.140 |
Why?
| | Fluid Therapy | 1 | 2020 | 147 | 0.140 |
Why?
| | Proportional Hazards Models | 6 | 2018 | 1325 | 0.140 |
Why?
| | Adolescent | 5 | 2021 | 22453 | 0.140 |
Why?
| | Epidemiology | 1 | 2018 | 33 | 0.140 |
Why?
| | Drug Users | 1 | 2018 | 42 | 0.130 |
Why?
| | Documentation | 1 | 2020 | 199 | 0.130 |
Why?
| | Vancomycin | 1 | 2018 | 93 | 0.130 |
Why?
| | Genes, rRNA | 1 | 2017 | 42 | 0.130 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2017 | 893 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1358 | 0.130 |
Why?
| | Streptococcus | 1 | 2017 | 29 | 0.130 |
Why?
| | Perioperative Care | 1 | 2020 | 231 | 0.130 |
Why?
| | Atherectomy, Coronary | 1 | 2017 | 10 | 0.130 |
Why?
| | Clostridium Infections | 1 | 2018 | 74 | 0.130 |
Why?
| | Coronary Stenosis | 1 | 2017 | 38 | 0.130 |
Why?
| | Antiviral Agents | 2 | 1994 | 768 | 0.130 |
Why?
| | History, 21st Century | 1 | 2018 | 219 | 0.130 |
Why?
| | Behavior, Addictive | 1 | 2018 | 88 | 0.130 |
Why?
| | Homeostasis | 1 | 2021 | 640 | 0.130 |
Why?
| | Coronary Occlusion | 1 | 2017 | 20 | 0.130 |
Why?
| | Antibodies | 8 | 1983 | 403 | 0.130 |
Why?
| | Antibodies, Monoclonal | 10 | 2016 | 1524 | 0.130 |
Why?
| | Data Collection | 1 | 2020 | 635 | 0.130 |
Why?
| | Dysbiosis | 1 | 2018 | 187 | 0.130 |
Why?
| | Contrast Media | 1 | 2020 | 488 | 0.130 |
Why?
| | Young Adult | 5 | 2021 | 14126 | 0.130 |
Why?
| | Psychological Trauma | 1 | 2017 | 57 | 0.120 |
Why?
| | Cocaine-Related Disorders | 1 | 2018 | 132 | 0.120 |
Why?
| | Myeloma Proteins | 8 | 1984 | 13 | 0.120 |
Why?
| | Hypertension | 1 | 2025 | 1264 | 0.120 |
Why?
| | Peroxidase | 2 | 1994 | 168 | 0.120 |
Why?
| | Binding Sites, Antibody | 6 | 1988 | 41 | 0.120 |
Why?
| | Population Surveillance | 1 | 2020 | 485 | 0.120 |
Why?
| | Antigens | 11 | 1979 | 347 | 0.120 |
Why?
| | Program Evaluation | 3 | 2017 | 949 | 0.120 |
Why?
| | Mice, Inbred Strains | 5 | 1987 | 397 | 0.120 |
Why?
| | Immunoglobulin G | 11 | 1988 | 893 | 0.120 |
Why?
| | Blood Transfusion | 2 | 2017 | 405 | 0.120 |
Why?
| | Infant, Newborn | 2 | 2018 | 6434 | 0.120 |
Why?
| | Comorbidity | 2 | 2018 | 1660 | 0.120 |
Why?
| | Career Choice | 1 | 2018 | 237 | 0.120 |
Why?
| | Vascular Calcification | 1 | 2017 | 110 | 0.120 |
Why?
| | Glucose | 1 | 2021 | 1049 | 0.120 |
Why?
| | Mycoplasma | 1 | 1995 | 5 | 0.120 |
Why?
| | Mycoplasma Infections | 1 | 1995 | 17 | 0.120 |
Why?
| | Femoral Artery | 1 | 2017 | 190 | 0.120 |
Why?
| | Cross Reactions | 5 | 1988 | 130 | 0.110 |
Why?
| | Medication Errors | 1 | 2016 | 83 | 0.110 |
Why?
| | Antibody Specificity | 10 | 1989 | 181 | 0.110 |
Why?
| | Research Report | 1 | 2016 | 87 | 0.110 |
Why?
| | Adipose Tissue | 1 | 2020 | 653 | 0.110 |
Why?
| | Algorithms | 2 | 2020 | 1839 | 0.110 |
Why?
| | Treatment Outcome | 10 | 2019 | 11695 | 0.110 |
Why?
| | Blood Glucose | 2 | 2024 | 2330 | 0.110 |
Why?
| | Hemorrhage | 2 | 2017 | 809 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1098 | 0.110 |
Why?
| | Saphenous Vein | 1 | 2014 | 37 | 0.110 |
Why?
| | Social Determinants of Health | 1 | 2018 | 301 | 0.110 |
Why?
| | Prognosis | 2 | 2021 | 4293 | 0.110 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 285 | 0.100 |
Why?
| | Drug-Eluting Stents | 1 | 2014 | 88 | 0.100 |
Why?
| | Arterial Occlusive Diseases | 1 | 2014 | 90 | 0.100 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 299 | 0.100 |
Why?
| | Antimicrobial Stewardship | 1 | 2016 | 130 | 0.100 |
Why?
| | Hydrogen Peroxide | 1 | 1995 | 336 | 0.100 |
Why?
| | Infant | 2 | 2018 | 10039 | 0.100 |
Why?
| | Premature Birth | 1 | 2017 | 380 | 0.100 |
Why?
| | Methionine Sulfoximine | 2 | 1990 | 2 | 0.100 |
Why?
| | Lymphocyte Depletion | 2 | 1990 | 132 | 0.100 |
Why?
| | Stents | 2 | 2014 | 556 | 0.100 |
Why?
| | Patient Selection | 2 | 2016 | 719 | 0.100 |
Why?
| | Carmustine | 2 | 1990 | 52 | 0.100 |
Why?
| | Renal Dialysis | 1 | 2017 | 462 | 0.090 |
Why?
| | Child, Preschool | 2 | 2018 | 11799 | 0.090 |
Why?
| | Aged, 80 and over | 6 | 2024 | 8279 | 0.090 |
Why?
| | Bone Marrow Transplantation | 2 | 1990 | 294 | 0.090 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 497 | 0.090 |
Why?
| | Chi-Square Distribution | 3 | 2018 | 529 | 0.090 |
Why?
| | Retrospective Studies | 10 | 2020 | 17101 | 0.090 |
Why?
| | Databases, Factual | 4 | 2019 | 1486 | 0.090 |
Why?
| | Immunoglobulin Allotypes | 3 | 1986 | 9 | 0.090 |
Why?
| | Nitrohydroxyiodophenylacetate | 2 | 1988 | 3 | 0.090 |
Why?
| | Antigens, Neoplasm | 4 | 1990 | 272 | 0.080 |
Why?
| | Rabbits | 15 | 1983 | 648 | 0.080 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1915 | 0.080 |
Why?
| | Coronary Disease | 1 | 2013 | 386 | 0.080 |
Why?
| | Bone Marrow | 2 | 1989 | 306 | 0.080 |
Why?
| | Sex Factors | 1 | 2017 | 2114 | 0.080 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 598 | 0.080 |
Why?
| | Hospitals, Veterans | 3 | 2018 | 259 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2026 | 2947 | 0.080 |
Why?
| | Military Personnel | 1 | 2018 | 747 | 0.080 |
Why?
| | Plasma Cells | 3 | 1976 | 79 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 2738 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 728 | 0.080 |
Why?
| | Insulin | 1 | 2021 | 2507 | 0.080 |
Why?
| | Antibodies, Anti-Idiotypic | 3 | 1985 | 51 | 0.080 |
Why?
| | Pediatrics | 1 | 2018 | 1115 | 0.080 |
Why?
| | Prevalence | 4 | 2018 | 2836 | 0.080 |
Why?
| | Biomarkers | 1 | 2021 | 4275 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3869 | 0.070 |
Why?
| | Stroke | 1 | 2018 | 1258 | 0.070 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 1988 | 21 | 0.070 |
Why?
| | Immunoglobulin Isotypes | 1 | 1988 | 35 | 0.070 |
Why?
| | Immune Sera | 11 | 1985 | 77 | 0.070 |
Why?
| | Glycoproteins | 1 | 1990 | 355 | 0.070 |
Why?
| | Immunoglobulin M | 6 | 1983 | 284 | 0.070 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 1986 | 85 | 0.070 |
Why?
| | Hospitalization | 2 | 2016 | 2434 | 0.070 |
Why?
| | Mice | 30 | 1989 | 18365 | 0.070 |
Why?
| | Species Specificity | 2 | 1988 | 574 | 0.070 |
Why?
| | Animals | 42 | 2021 | 38109 | 0.070 |
Why?
| | Nitrophenols | 1 | 1987 | 29 | 0.070 |
Why?
| | Colorado | 1 | 2018 | 4564 | 0.070 |
Why?
| | Adjuvants, Immunologic | 2 | 1988 | 245 | 0.070 |
Why?
| | Antibodies, Neoplasm | 2 | 1979 | 35 | 0.070 |
Why?
| | Cell Line | 6 | 1995 | 2882 | 0.070 |
Why?
| | Immunoglobulins | 7 | 1984 | 160 | 0.070 |
Why?
| | Receptors, Antigen, B-Cell | 5 | 1979 | 134 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 1986 | 72 | 0.060 |
Why?
| | Killer Cells, Natural | 2 | 1988 | 469 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2014 | 1099 | 0.060 |
Why?
| | Immunoglobulin Variable Region | 3 | 1983 | 80 | 0.060 |
Why?
| | Immunoelectrophoresis | 11 | 1976 | 13 | 0.060 |
Why?
| | Genes, MHC Class II | 2 | 1983 | 76 | 0.060 |
Why?
| | CpG Islands | 1 | 2025 | 165 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 966 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6053 | 0.060 |
Why?
| | Anthropometry | 1 | 2025 | 200 | 0.050 |
Why?
| | Body Size | 1 | 2025 | 95 | 0.050 |
Why?
| | Workflow | 1 | 2026 | 185 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2016 | 1980 | 0.050 |
Why?
| | p-Azobenzenearsonate | 1 | 1983 | 5 | 0.050 |
Why?
| | B-Lymphocytes | 3 | 1979 | 877 | 0.050 |
Why?
| | Azo Compounds | 1 | 1983 | 30 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2024 | 521 | 0.050 |
Why?
| | Mice, Inbred A | 3 | 1988 | 48 | 0.050 |
Why?
| | Lymphocytes | 3 | 1979 | 382 | 0.050 |
Why?
| | Immunoglobulin kappa-Chains | 2 | 1979 | 23 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 1983 | 206 | 0.040 |
Why?
| | Phospholipases A2, Calcium-Independent | 1 | 2021 | 18 | 0.040 |
Why?
| | Adsorption | 4 | 1975 | 157 | 0.040 |
Why?
| | Kinetics | 6 | 1989 | 1629 | 0.040 |
Why?
| | Diet Surveys | 1 | 2021 | 91 | 0.040 |
Why?
| | Binding, Competitive | 4 | 1983 | 193 | 0.040 |
Why?
| | Acyltransferases | 1 | 2021 | 78 | 0.040 |
Why?
| | Antibody Formation | 5 | 1987 | 294 | 0.040 |
Why?
| | Microsomes | 4 | 1975 | 33 | 0.040 |
Why?
| | Radiometry | 1 | 2021 | 57 | 0.040 |
Why?
| | Lipase | 1 | 2021 | 75 | 0.040 |
Why?
| | Immunoglobulin Fab Fragments | 3 | 2016 | 56 | 0.040 |
Why?
| | Neoplasms, Experimental | 4 | 1979 | 173 | 0.040 |
Why?
| | Lymph Nodes | 5 | 1985 | 502 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 685 | 0.040 |
Why?
| | Protons | 1 | 2021 | 95 | 0.040 |
Why?
| | Forehead | 1 | 2020 | 5 | 0.040 |
Why?
| | DNA Methylation | 1 | 2025 | 683 | 0.040 |
Why?
| | Genetic Markers | 1 | 2021 | 331 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 2020 | 82 | 0.040 |
Why?
| | Phantoms, Imaging | 1 | 2021 | 158 | 0.040 |
Why?
| | Buthionine Sulfoximine | 2 | 1990 | 9 | 0.040 |
Why?
| | Patient Readmission | 2 | 2017 | 759 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1990 | 1958 | 0.040 |
Why?
| | Sodium Bicarbonate | 1 | 2020 | 47 | 0.040 |
Why?
| | Mouth | 1 | 2020 | 88 | 0.040 |
Why?
| | Genomics | 1 | 2025 | 836 | 0.040 |
Why?
| | HIV Infections | 1 | 1995 | 3154 | 0.040 |
Why?
| | Gene-Environment Interaction | 1 | 2021 | 180 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2020 | 122 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 732 | 0.040 |
Why?
| | Immunoglobulin mu-Chains | 1 | 1979 | 8 | 0.040 |
Why?
| | Multiple Myeloma | 3 | 1984 | 304 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2020 | 139 | 0.040 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.040 |
Why?
| | Immunoglobulin Light Chains | 1 | 1979 | 51 | 0.040 |
Why?
| | Oceania | 1 | 2018 | 5 | 0.040 |
Why?
| | Child Behavior | 1 | 2021 | 236 | 0.040 |
Why?
| | Carrier Proteins | 1 | 1983 | 737 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2019 | 69 | 0.040 |
Why?
| | Drug Synergism | 2 | 1990 | 357 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 854 | 0.040 |
Why?
| | Antigens, Surface | 1 | 1979 | 157 | 0.040 |
Why?
| | Antigens, CD | 2 | 1993 | 555 | 0.040 |
Why?
| | Blood Pressure | 1 | 2025 | 1769 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 108 | 0.040 |
Why?
| | Teratoma | 1 | 1979 | 120 | 0.040 |
Why?
| | Quality Improvement | 2 | 2018 | 1291 | 0.030 |
Why?
| | Cattle | 1 | 2021 | 1000 | 0.030 |
Why?
| | Genes, Regulator | 1 | 1978 | 35 | 0.030 |
Why?
| | Peptides | 4 | 2016 | 998 | 0.030 |
Why?
| | Mice, Inbred C57BL | 9 | 1988 | 5997 | 0.030 |
Why?
| | Skin | 1 | 2023 | 758 | 0.030 |
Why?
| | Mice, Inbred C3H | 4 | 1988 | 251 | 0.030 |
Why?
| | Erythrocytes | 3 | 1989 | 757 | 0.030 |
Why?
| | Glutathione | 2 | 1990 | 375 | 0.030 |
Why?
| | North America | 1 | 2018 | 310 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3608 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2020 | 285 | 0.030 |
Why?
| | Echocardiography, Stress | 1 | 2017 | 29 | 0.030 |
Why?
| | Europe | 1 | 2018 | 412 | 0.030 |
Why?
| | Proteomics | 1 | 2024 | 1195 | 0.030 |
Why?
| | Punctures | 1 | 2017 | 40 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2020 | 378 | 0.030 |
Why?
| | Dose-Response Relationship, Immunologic | 2 | 1989 | 76 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 2020 | 316 | 0.030 |
Why?
| | Transfusion Reaction | 1 | 2017 | 63 | 0.030 |
Why?
| | Fibrosarcoma | 1 | 1976 | 23 | 0.030 |
Why?
| | Self Report | 1 | 2021 | 873 | 0.030 |
Why?
| | Hematopoietic Stem Cells | 2 | 1990 | 420 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2017 | 189 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 91 | 0.030 |
Why?
| | Drug Labeling | 1 | 2016 | 37 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2020 | 760 | 0.030 |
Why?
| | Drug Utilization Review | 1 | 2016 | 61 | 0.030 |
Why?
| | Adolescent Behavior | 1 | 2021 | 501 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 249 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 1095 | 0.030 |
Why?
| | Vasodilator Agents | 1 | 2017 | 331 | 0.030 |
Why?
| | Risk-Taking | 1 | 2018 | 328 | 0.030 |
Why?
| | Health Behavior | 1 | 2021 | 786 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 476 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 6 | 1993 | 331 | 0.030 |
Why?
| | Fluorescence | 1 | 1995 | 161 | 0.030 |
Why?
| | Device Removal | 1 | 2016 | 143 | 0.030 |
Why?
| | Cell Survival | 2 | 1990 | 1098 | 0.030 |
Why?
| | Immunodiffusion | 7 | 1974 | 12 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2021 | 1167 | 0.030 |
Why?
| | Bioprosthesis | 1 | 2014 | 40 | 0.030 |
Why?
| | Phytohemagglutinins | 1 | 1994 | 29 | 0.030 |
Why?
| | HIV Core Protein p24 | 1 | 1994 | 32 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1077 | 0.030 |
Why?
| | Angina, Unstable | 1 | 2014 | 82 | 0.030 |
Why?
| | Immune Tolerance | 3 | 1993 | 379 | 0.030 |
Why?
| | Radioimmunoassay | 1 | 1994 | 165 | 0.030 |
Why?
| | Catalase | 1 | 1994 | 130 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2092 | 0.030 |
Why?
| | Health Promotion | 1 | 2020 | 774 | 0.020 |
Why?
| | Metals | 1 | 2014 | 142 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1540 | 0.020 |
Why?
| | Mortality | 1 | 2016 | 376 | 0.020 |
Why?
| | Polystyrenes | 1 | 1993 | 37 | 0.020 |
Why?
| | Inflammation | 1 | 2024 | 2880 | 0.020 |
Why?
| | CD8 Antigens | 1 | 1993 | 72 | 0.020 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1993 | 100 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 2018 | 592 | 0.020 |
Why?
| | Lymphokines | 1 | 1993 | 130 | 0.020 |
Why?
| | Fibronectins | 1 | 1993 | 136 | 0.020 |
Why?
| | Patient Safety | 1 | 2016 | 349 | 0.020 |
Why?
| | CD4 Antigens | 1 | 1993 | 139 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1563 | 0.020 |
Why?
| | Immunization, Passive | 2 | 1989 | 87 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 1993 | 851 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2118 | 0.020 |
Why?
| | Mental Health | 1 | 2018 | 792 | 0.020 |
Why?
| | Heparin | 1 | 1993 | 244 | 0.020 |
Why?
| | Pilot Projects | 1 | 2017 | 1890 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2017 | 791 | 0.020 |
Why?
| | Epitopes | 4 | 1979 | 485 | 0.020 |
Why?
| | Acrylamides | 1 | 1972 | 70 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 2 | 1989 | 223 | 0.020 |
Why?
| | CD52 Antigen | 1 | 1990 | 3 | 0.020 |
Why?
| | Blood Proteins | 1 | 1973 | 249 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1813 | 0.020 |
Why?
| | Thymus Neoplasms | 1 | 1990 | 27 | 0.020 |
Why?
| | Thymoma | 1 | 1990 | 36 | 0.020 |
Why?
| | Mice, Inbred DBA | 2 | 1988 | 187 | 0.020 |
Why?
| | Isoelectric Focusing | 2 | 1988 | 30 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1993 | 389 | 0.020 |
Why?
| | Virus Replication | 1 | 1993 | 529 | 0.020 |
Why?
| | Proteins | 2 | 1993 | 1022 | 0.020 |
Why?
| | Interleukin-2 | 1 | 1990 | 437 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2852 | 0.020 |
Why?
| | Dinitrophenols | 1 | 1988 | 7 | 0.020 |
Why?
| | Trinitrobenzenes | 1 | 1988 | 14 | 0.020 |
Why?
| | 2,4-Dinitrophenol | 1 | 1988 | 9 | 0.020 |
Why?
| | Rats, Nude | 1 | 1988 | 25 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 1990 | 919 | 0.020 |
Why?
| | Esterases | 3 | 1968 | 9 | 0.020 |
Why?
| | Antigen-Antibody Reactions | 3 | 1975 | 50 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 1969 | 232 | 0.020 |
Why?
| | Oxidative Stress | 1 | 1995 | 1339 | 0.020 |
Why?
| | Hybridomas | 2 | 1993 | 234 | 0.020 |
Why?
| | Lymphoma | 1 | 1990 | 233 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 1989 | 320 | 0.020 |
Why?
| | Medicare | 1 | 2013 | 887 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1989 | 1048 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2020 | 2920 | 0.020 |
Why?
| | Sheep | 4 | 1981 | 880 | 0.020 |
Why?
| | Rats | 7 | 1988 | 5614 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 1993 | 2157 | 0.020 |
Why?
| | Immunotherapy | 2 | 1989 | 657 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 1988 | 315 | 0.020 |
Why?
| | Isoelectric Point | 1 | 1986 | 23 | 0.020 |
Why?
| | Electrophoresis | 4 | 1968 | 31 | 0.020 |
Why?
| | Chromium Radioisotopes | 1 | 1986 | 4 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 1989 | 573 | 0.020 |
Why?
| | Abortion, Veterinary | 1 | 1986 | 2 | 0.020 |
Why?
| | Heart Failure | 1 | 2020 | 2323 | 0.020 |
Why?
| | Methods | 2 | 1979 | 69 | 0.010 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1969 | 372 | 0.010 |
Why?
| | Fetal Resorption | 1 | 1985 | 2 | 0.010 |
Why?
| | Fetal Death | 1 | 1985 | 58 | 0.010 |
Why?
| | Neoplasm Transplantation | 4 | 1984 | 252 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2013 | 5417 | 0.010 |
Why?
| | Precipitin Tests | 2 | 1975 | 93 | 0.010 |
Why?
| | Cell Nucleus | 4 | 1968 | 619 | 0.010 |
Why?
| | Immunoglobulin Constant Regions | 1 | 1983 | 7 | 0.010 |
Why?
| | H-2 Antigens | 2 | 1986 | 111 | 0.010 |
Why?
| | Phenylalanine | 1 | 1963 | 71 | 0.010 |
Why?
| | Acetates | 1 | 1963 | 80 | 0.010 |
Why?
| | Cells, Cultured | 2 | 1990 | 4155 | 0.010 |
Why?
| | Interferon Type I | 1 | 1984 | 145 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 1969 | 783 | 0.010 |
Why?
| | Chromatography | 2 | 1973 | 27 | 0.010 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1983 | 131 | 0.010 |
Why?
| | Perfusion | 1 | 1963 | 250 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1981 | 49 | 0.010 |
Why?
| | Clone Cells | 2 | 1979 | 266 | 0.010 |
Why?
| | Receptors, Fc | 1 | 1981 | 55 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 2 | 1993 | 51 | 0.010 |
Why?
| | Research | 1 | 1963 | 431 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 1979 | 164 | 0.010 |
Why?
| | Papain | 1 | 1979 | 3 | 0.010 |
Why?
| | Thymus Gland | 1 | 1979 | 311 | 0.010 |
Why?
| | Genes | 1 | 1978 | 226 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1978 | 273 | 0.010 |
Why?
| | Immunosorbent Techniques | 1 | 1976 | 18 | 0.010 |
Why?
| | Spleen | 3 | 1979 | 508 | 0.010 |
Why?
| | Sarcoma, Experimental | 1 | 1976 | 6 | 0.010 |
Why?
| | Mitochondria | 1 | 1963 | 984 | 0.010 |
Why?
| | Vaccination | 1 | 1985 | 1423 | 0.010 |
Why?
| | Horseradish Peroxidase | 1 | 1976 | 26 | 0.010 |
Why?
| | Glutaral | 1 | 1975 | 13 | 0.010 |
Why?
| | Antigens, Heterophile | 1 | 1975 | 5 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1976 | 151 | 0.010 |
Why?
| | Immunoassay | 1 | 1976 | 109 | 0.010 |
Why?
| | Cytoplasm | 1 | 1976 | 269 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1976 | 370 | 0.010 |
Why?
| | Antibody-Producing Cells | 1 | 1974 | 29 | 0.010 |
Why?
| | Cell Differentiation | 2 | 1974 | 2050 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 1974 | 131 | 0.010 |
Why?
| | Globulins | 1 | 1973 | 1 | 0.010 |
Why?
| | Chloroform | 1 | 1973 | 2 | 0.010 |
Why?
| | Immunoglobulin Fragments | 1 | 1973 | 11 | 0.010 |
Why?
| | Thermolysin | 1 | 1993 | 4 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 1983 | 2609 | 0.010 |
Why?
| | Blood Protein Electrophoresis | 1 | 1973 | 6 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 1976 | 458 | 0.010 |
Why?
| | Absorption | 1 | 1993 | 60 | 0.010 |
Why?
| | CD57 Antigens | 1 | 1993 | 18 | 0.010 |
Why?
| | Chick Embryo | 1 | 1973 | 132 | 0.010 |
Why?
| | Solubility | 1 | 1973 | 242 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 1993 | 200 | 0.010 |
Why?
| | Microspheres | 1 | 1993 | 142 | 0.010 |
Why?
| | Hydrolysis | 1 | 1993 | 199 | 0.010 |
Why?
| | Iodine Radioisotopes | 1 | 1993 | 137 | 0.010 |
Why?
| | Chickens | 1 | 1973 | 191 | 0.010 |
Why?
| | Immunochemistry | 1 | 1972 | 12 | 0.010 |
Why?
| | Immunologic Techniques | 1 | 1972 | 38 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1972 | 166 | 0.010 |
Why?
| | Cell Membrane | 1 | 1975 | 706 | 0.010 |
Why?
| | Animals, Newborn | 1 | 1974 | 902 | 0.010 |
Why?
| | Muramidase | 1 | 1972 | 67 | 0.010 |
Why?
| | Leukocytes | 1 | 1973 | 295 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 1972 | 145 | 0.010 |
Why?
| | Cholinesterases | 2 | 1968 | 9 | 0.010 |
Why?
| | Deoxyribonucleases | 2 | 1968 | 24 | 0.010 |
Why?
| | Aldehydes | 1 | 1972 | 142 | 0.010 |
Why?
| | L-Lactate Dehydrogenase | 2 | 1968 | 115 | 0.010 |
Why?
| | Lipoproteins | 1 | 1971 | 169 | 0.010 |
Why?
| | Blotting, Western | 1 | 1993 | 1187 | 0.000 |
Why?
| | Protein Conformation | 1 | 1993 | 946 | 0.000 |
Why?
| | Endoplasmic Reticulum | 1 | 1971 | 266 | 0.000 |
Why?
| | Ethanol | 1 | 1973 | 627 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1993 | 2931 | 0.000 |
Why?
| | Protein Binding | 1 | 1993 | 2276 | 0.000 |
Why?
| | Liver Diseases | 1 | 1969 | 304 | 0.000 |
Why?
| | Enzymes | 1 | 1966 | 65 | 0.000 |
Why?
| | Genetic Variation | 1 | 1970 | 984 | 0.000 |
Why?
| | Fetal Viability | 1 | 1985 | 3 | 0.000 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1986 | 177 | 0.000 |
Why?
| | Mice, Inbred CBA | 1 | 1985 | 57 | 0.000 |
Why?
| | Pronase | 1 | 1981 | 5 | 0.000 |
Why?
| | Rosette Formation | 1 | 1981 | 14 | 0.000 |
Why?
| | Trypsin | 1 | 1981 | 76 | 0.000 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1985 | 668 | 0.000 |
Why?
| | Contact Inhibition | 2 | 1970 | 5 | 0.000 |
Why?
| | Lymphocyte Activation | 1 | 1985 | 1126 | 0.000 |
Why?
| | Culture Techniques | 2 | 1970 | 67 | 0.000 |
Why?
| | Ascitic Fluid | 1 | 1979 | 15 | 0.000 |
Why?
| | Microscopy, Electron | 2 | 1970 | 415 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1981 | 364 | 0.000 |
Why?
| | Epithelium | 2 | 1970 | 314 | 0.000 |
Why?
| | beta-Galactosidase | 1 | 1979 | 77 | 0.000 |
Why?
| | Cell Cycle | 1 | 1981 | 597 | 0.000 |
Why?
| | Placenta | 1 | 1985 | 780 | 0.000 |
Why?
| | Fibroblasts | 2 | 1970 | 1034 | 0.000 |
Why?
| | Neuraminic Acids | 1 | 1972 | 1 | 0.000 |
Why?
| | Neuraminidase | 1 | 1972 | 25 | 0.000 |
Why?
| | Densitometry | 1 | 1972 | 38 | 0.000 |
Why?
| | Vibrio cholerae | 1 | 1972 | 14 | 0.000 |
Why?
| | Ultracentrifugation | 1 | 1972 | 51 | 0.000 |
Why?
| | Microsomes, Liver | 1 | 1972 | 85 | 0.000 |
Why?
| | Leukemia Virus, Murine | 1 | 1970 | 17 | 0.000 |
Why?
| | Intestines | 1 | 1972 | 358 | 0.000 |
Why?
|
|
Stanislawski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|